Skip to main content
Premium Trial:

Request an Annual Quote

Nasdaq Warns Biocept Over Listing Requirement

NEW YORK – Biocept said today that it received a notice from Nasdaq last week that it has failed to comply with a minimum bid price rule, which requires that companies listed on the Nasdaq Capital Market maintain a minimum closing bid price of at least $1.00 per share. As a result, it could face delisting action.

The firm has a 180 calendar-day grace period to regain compliance, by maintaining a minimum closing bid price for its stock of at least $1.00 per share for a minimum of 10 consecutive business days during the 180-calendar-day grace period.

In a document filed with the US Securities and Exchange Commission, Biocept said it is monitoring the bid price of its common stock and will consider options available to it to potentially achieve compliance.

In mid-day trading on the Nasdaq, Biocept's shares were down 5 percent at $0.77.

The Scan

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.

Estonian Biobank Team Digs into Results Return Strategies, Experiences

Researchers in the European Journal of Human Genetics outline a procedure developed for individual return of results for the population biobank, along with participant experiences conveyed in survey data.

Rare Recessive Disease Insights Found in Individual Genomes

Researchers predict in Genome Medicine cross-population deletions and autosomal recessive disease impacts by analyzing recurrent nonallelic homologous recombination-related deletions.

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.